Optimizing the Percutaneous Interventional Outcomes for Patients With Diabetes Mellitus: Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) Diabetic Substudy
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Background —Stenting likely decreases the need for target-vessel revascularization procedures in diabetic patients compared with balloon angioplasty. However, the efficacy of stenting with platelet glycoprotein IIb/IIIa blockade has not yet been assessed in diabetics. Methods and Results —We analyzed the outcomes of 491 diabetic patients within the multicenter Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial (EPISTENT). Diabetic patients were a prospectively defined subset: 173 were randomized to stent-placebo, 162 to stent-abciximab, and 156 to balloon angioplasty–abciximab. The main end point for this analysis was combined 6-month death, myocardial infarction (MI), or target-vessel revascularization (TVR). The composite end point occurred in 25.2% of stent-placebo, 23.4% of balloon-abciximab, and 13.0% of stent-abciximab patients ( P =0.005). Abciximab therapy, irrespective of revascularization strategy (stent or balloon angioplasty), resulted in a significant reduction in the 6-month death or MI rate: 12.7% for stent-placebo, 7.8% for balloon angioplasty–abciximab, and 6.2% for the stent-abciximab group ( P =0.029). The 6-month TVR rate was 16.6% for stent-placebo, 18.4% for balloon-abciximab, and 8.1% for stent-abciximab ( P =0.021). Compared with stent-placebo, stent-abciximab therapy was associated with a significant increase in angiographic net gain (0.88 versus 0.55 mm; P =0.011) and a decrease in the late loss index (0.40 versus 0.60 mm; P =0.061). The 1-year mortality rate for diabetics was 4.1% for stent-placebo and 1.2% for stent-abciximab patients ( P =0.11). Conclusions —The combination of stenting and abciximab therapy among diabetics resulted in a significant reduction in 6-month rates of death, MI, and TVR compared with stent-placebo or balloon-abciximab therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1994) · New England Journal of Medicine · doi:10.1056/nejm199404073301402 · Cited by 2,589
(1997) · New England Journal of Medicine · doi:10.1056/nejm199706123362401 · Cited by 1,883
Epistent Investigators, T. (1998) · The Lancet · doi:10.1016/s0140-6736(98)06113-3 · Cited by 1,346
Topol, E. J. (1998) · The Lancet · doi:10.1016/s0140-6736(98)85010-1 · Cited by 1,095
Self-citationBrener, S. J., Barr, L. A., Burchenal, J. E. B., Katz, S., George, B. S., Jones, A. A., Cohen, E. D., Gainey, P. C., White, H. J., Cheek, H. B., et al. (1998) · Circulation · doi:10.1161/01.cir.98.8.734 · Cited by 722
Self-citationPredictive Factors of Restenosis After Coronary Stent Placement
Kastrati, A., Schömig, A., Elezi, S., Schühlen, H., Dirschinger, J., Hadamitzky, M., Wehinger, A., Hausleiter, J., Walter, H., & Neumann, F.-J. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00334-3 · Cited by 685
Investigators, T. B. (1997) · Circulation · doi:10.1161/01.cir.96.6.1761 · Cited by 619
Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement
Elezi, S., Kastrati, A., Pache, J., Wehinger, A., Hadamitzky, M., Dirschinger, J., Neumann, F.-J., & Schömig, A. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00467-7 · Cited by 495
Abizaid, A., Kornowski, R., Mintz, G. S., Hong, M. K., Abizaid, A. S., Mehran, R., Pichard, A. D., Kent, K. M., Satler, L. F., Wu, H., et al. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00286-1 · Cited by 458
Cited by
WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., Jacobs, A. K., Kern, M. J., King, S. B., Morrison, D. A., O’Neill, W. W., Schaff, H. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.170815 · Cited by 2,218
Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part I
Creager, M. A., Lüscher, T. F., of, P. W. T. A., Cosentino, F., & Beckman, J. A. (2003) · Circulation · doi:10.1161/01.cir.0000091257.27563.32 · Cited by 1,650
Guidelines for Percutaneous Coronary Interventions
Silber, S., Albertsson, P., Avilés, F. F., Camici, P. G., Colombo, A., Hamm, C., Jørgensen, E., Marco, J., Nordrehaug, J.-E., Ruzyllo, W., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi138 · Cited by 1,609
Platelet Glycoprotein IIb/IIIa Inhibition with Coronary Stenting for Acute Myocardial Infarction
Montalescot, G., Barragan, P., Wittenberg, O., Ecollan, P., Elhadad, S., Villain, P., Boulenc, J.-M., Morice, M.-C., Maillard, L., Pansiéri, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106213442503 · Cited by 1,186
Patrono, C., Coller, B., Dalen, J. E., Fitz Gerald, G. A., Fuster, V., Gent, M., Hirsh, J., & Roth, G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.39s · Cited by 963
Wiviott, S. D., Braunwald, E., Angiolillo, D. J., Meisel, S., Dalby, A. J., Verheugt, F. W. A., Goodman, S. G., Corbalan, R., Purdy, D. A., Murphy, S. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.791061 · Cited by 754
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects
Patrono, C., Coller, B., FitzGerald, G. A., Hirsh, J., & Roth, G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.234s · Cited by 671
Smith, S. C., Dove, J. T., Jacobs, A. K., Kennedy, J. W., Kereiakes, D., Kern, M. J., Kuntz, R. E., Popma, J. J., Schaff, H. V., Williams, D. O., et al. (2001) · Circulation · doi:10.1161/01.cir.103.24.3019 · Cited by 608
ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention
Smith, S. C., Feldman, T. E., Hirshfeld, J. W., Jacobs, A. K., Kern, M. J., King, S. B., Morrison, D. A., O’Neill, W. W., Schaff, H. V., Whitlow, P. L., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.12.001 · Cited by 532
Moreno, P. R., Murcia, A. M., Palacios, I. F., Leon, M. N., Bernardi, V. H., Fuster, V., & Fallon, J. T. (2000) · Circulation · doi:10.1161/01.cir.102.18.2180 · Cited by 477
Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus
Bhatt, D. L., Marso, S. P., Hirsch, A. T., Ringleb, P. A., Hacke, W., & Topol, E. J. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02567-5 · Cited by 409
Self-citationClinical Aspects of Platelet Inhibitors and Thrombus Formation
Meadows, T. A., & Bhatt, D. L. (2007) · Circulation Research · doi:10.1161/01.res.0000264509.36234.51 · Cited by 351
Self-citationAbizaid, A., Costa, M. A., Centemero, M., Abizaid, A. S., Legrand, V. M. G., Limet, R. V., Schuler, G., Mohr, F. W., Lindeboom, W., Sousa, A. G. M. R., et al. (2001) · Circulation · doi:10.1161/hc3101.093700 · Cited by 337
Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group I: Epidemiology
Howard, B. V., Rodriguez, B. L., Bennett, P. H., Harris, M. I., Hamman, R., Kuller, L. H., Pearson, T. A., & Wylie-Rosett, J. (2002) · Circulation · doi:10.1161/01.cir.0000013953.41667.09 · Cited by 308
Mehilli, J., Kastrati, A., Schühlen, H., Dibra, A., Dotzer, F., von Beckerath, N., Bollwein, H., Pache, J., Dirschinger, J., Berger, P. P., et al. (2004) · Circulation · doi:10.1161/01.cir.0000148956.93631.4d · Cited by 303
Franklin, K. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.13.1457 · Cited by 295
Management of coronary artery disease: therapeutic options in patients with diabetes
Hammoud, T., Tanguay, J.-F., & Bourassa, M. G. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00732-4 · Cited by 256
Self-citationBarsness, G. W., Holmes, D. R., & Gersh, B. J. (2005) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2005.06.006 · Cited by 5
Metadata
- Authors
- Marso, S. P., Lincoff, A. M., Ellis, S. G., Bhatt, D. L., Tanguay, J.-F., Kleiman, N. S., Hammoud, T., Booth, J. E., Sapp, S. K., & Topol, E. J.
- Venue
- Circulation
- Published
- 1999-12-21
- Volume
- 100
- Issue
- 25
- Pages
- 2477-2484
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2120786522
- Cited by
- 288
- References
- 25
- FWCI
- 29.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.